DNA Microarray Market - By Product (Consumables, Instruments), Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays), Application (Gene Expression Analysis), End-user (Academic & Research Institute), Global Forecast (2023 – 2032)

DNA Microarray Market Size

DNA Microarray Market size accounted for USD 3.4 billion in 2022 and is estimated to grow at 8.7% to reach USD 7.8 billion by 2032. The adoption of DNA microarrays has been experiencing remarkable growth across a multitude of scientific and medical applications.
 

Ongoing advancements in genomics have unveiled the complex genetic foundations of various diseases, spurring the need for high-throughput tools such as DNA microarrays to comprehensively analyse gene expression and genomic alterations. Also, DNA microarrays have become crucial in biomedical research, empowering scientists to simultaneously investigate thousands of genes, facilitating groundbreaking discoveries in disease mechanisms, drug responses, and the identification of crucial biomarkers. Such associated advantages is expected to supplement market size.
 

A DNA microarray, also known as a DNA chip or gene chip, is a powerful laboratory tool used in molecular biology and genomics to analyse the expression levels of thousands of genes simultaneously. It allows researchers to study how genes are turned on or off in a cell or tissue sample, providing valuable insights into gene regulation, function, and their roles in various biological processes.
 

COVID-19 Impact

The global DNA microarray market experienced a favourable effect due to the COVID-19 pandemic. One significant positive impact of the pandemic was the accelerated adoption of DNA microarrays in research and diagnostics related to COVID-19 itself. These versatile tools proved crucial for studying the virus's genetic makeup, tracking its mutations, and understanding its impact on human gene expression.
 

Also, DNA microarrays allowed researchers to identify potential drug targets, study host responses to the virus, and develop diagnostic tests, including the rapid development of mRNA-based vaccines such as those from Pfizer-BioNTech and Moderna. Further, DNA microarrays have played a pivotal role in building this infrastructure by enhancing the understanding of infectious diseases, host-pathogen interactions, and immune responses. This increased awareness of the value of genomics tools attracted significant investment and innovation in the field, thereby fostered market growth during the pandemic.
 

DNA Microarray Market Trends

The growing prevalence of genetic disorders and cancers has emerged as a significant driver, propelling the expansion of the market. For instance, according to the World Health Organization (WHO), genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, account for up to 30% of paediatric hospital admissions and cause about 50% of childhood deaths in industrialized countries. Similarly, as per American Cancer Society report, in 2022, there was an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. Thus, rising cases of genetic disorders and cancers necessitate comprehensive genetic profiling and diagnostics for accurate disease identification.
 

DNA Microarray Market Restraint

One significant restraint impeding the growth of the market is the high cost associated with DNA sequencing. While DNA microarrays offer valuable insights into gene expression and genetic variations, the expenses incurred during sequencing procedures can be substantial. This cost comprises not only the acquisition of the microarray technology itself but also the expenses related to sample preparation, data analysis, and maintenance of sophisticated equipment. High initial capital investments and ongoing operational costs can deter smaller research laboratories and healthcare facilities with limited budgets from adopting DNA microarray technology. Therefore, the cost factor can limit the scalability of projects and research initiatives, especially in resource-constrained settings. Thus, the aforementioned factor is expected to hamper the market trends.
 

DNA Microarray Market Analysis

By product, the DNA microarray market is classified into consumables, instruments, and software & services. The consumables segment accounted for 46.7% of the business share in 2022 and is projected to witness significant growth over the analysis timeframe. This segment includes various components necessary for DNA microarray experiments, such as arrays, reagents, buffers, and other consumables. The growing adoption of DNA microarray technology across diverse fields, including genomics research, clinical diagnostics, and drug development, has led to a continuous need for these essential components. Moreover, the shift towards precision medicine and pharmacogenomics has expanded the scope of DNA microarray applications. These applications often require tailored consumables to meet specific research and diagnostic needs, further driving market progress.
 

Based on type, the DNA microarray market is segmented into complementary DNA microarrays, oligonucleotide DNA microarrays, and other types. The complementary DNA microarrays segment accounted for 51.8% of the market share in 2022. The advancement of biotechnology and molecular biology techniques has led to continuous improvements in cDNA microarray technology. This includes the development of more efficient and accurate cDNA synthesis methods, enhanced probe design, and improvements in the overall sensitivity and specificity of cDNA microarrays. These advancements have made cDNA microarrays even more powerful and reliable for researchers, driving their adoption.
 

Additionally, researchers across various disciplines, including molecular biology, genetics, and pharmaceuticals, rely on cDNA microarrays to unravel complex gene regulation networks, identify disease markers, and elucidate critical biological pathways.
 

Based on application, the DNA microarray market is segmented into gene expression analysis, genotyping, transcription factor binding analysis, and other applications. The genotyping segment is projected to witness significant growth of 9.2% over the analysis timeframe. The rising research and development funding dedicated to precision medicine and strategic initiatives undertaken by industry players are expected to contribute to genotyping segment growth.
 

For instance, in May 2022, Thermo Fisher Scientific partnered with Qatar Genome Program (QGP), a member of Qatar Foundation (QF), to accelerate genomic research and clinical applications of predictive genomics in Qatar. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom custom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. Such initiatives by key market player is expected to accelerate market expansion.
 

Based on end-user, the DNA microarray market is segmented into academic & research institute, pharmaceutical and biotechnology companies, diagnostic centers, hospitals and clinics, and other end-users. The academic & research institutes segment is expected to reach USD 2.7 billion by end of 2032. Academic & research institutions play a central role in pushing the boundaries of genomics research and its applications. They utilize DNA microarrays to conduct fundamental research across various fields, including molecular biology, genetics, neuroscience, and oncology, thereby fueling the market trends. Also, with increased investment in genomics, these organizations have the financial resources to acquire cutting-edge DNA microarray technology and conduct large-scale genomic studies, thus bolsters the growth of the market.
 

North America DNA microarray market accounted for 42.1% business share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. A prominent growth driver for the market in North America is the region's robust investment in cutting-edge research and development initiatives. Also, strategic collaborations between research institutions and industry leaders, as well as government initiatives supporting genomics research, further stimulate market share. Further, the region's strong healthcare infrastructure and well-established regulatory frameworks for medical devices ensure the timely adoption and compliance of DNA microarrays in clinical settings, thereby augmenting the regional market demand.
 

DNA Microarray Market Share

Major market players operating in the DNA microarray market include:

• Thermo Fisher Scientific, Inc
• QIAGEN
• Illumina, Inc.
• Agilent Technologies, Inc
• Merck & Co., Inc.
• bioMérieux SA

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

DNA Microarray Industry News:

• In August 2022, Thermo Fisher Scientific launched a new chromosomal microarray, the Applied Biosystem CytoScan HD Accel array, to improve cytogenetic research lab productivity, efficiency, and profitability with two-day turnaround time. This strategy helped the company to expand their product portfolio.
   
• In March 2020, Agilent Technologies Inc. launched three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research. The new Agilent GenetiSure Cyto microarrays include updated, clinically relevant content from respected databases. This strategy helped the company to expand their product offering, thereby generating revenue from its sales.
   

The DNA microarray market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product

• Consumables
• Instruments
• Software & services

By Type  

• Complementary DNA microarrays
• Oligonucleotide DNA microarrays
• Other types

By Application  

• Gene expression analysis
• Genotyping
• Transcription factor binding analysis
• Other applications

By End-user

• Academic & research institute
• Pharmaceutical and biotechnology companies
• Diagnostic centers
• Hospitals and clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa